c‐Abl activates p38 MAPK independently of its tyrosine kinase activity: Implications in cisplatin‐based therapy

Activation of p38 MAPK is a critical requisite for the therapeutics activity of the antitumor agent cisplatin. In this sense, a growing body of evidences supports the role of c‐Abl as a major determinant of p38 MAPK activation, especially in response to genotoxic stress when triggered by cisplatin....

Ausführliche Beschreibung